Financial Data and Key Metrics Changes - PetVivo reported a revenue growth of 17% for fiscal year 2025, totaling a record $1,100,000, driven largely by an expanding nationwide distributor network [4][8] - Gross profit was $995,000, representing 87.8% of revenues, which is a decrease from 89.5% in fiscal year 2024 [9] - Operating expenses decreased by 21% to $9,100,000, primarily due to a strategic cost reduction and restructuring program [9] - Net loss improved by 27% to $8,000,000 or $0.39 per share, compared to a net loss of $11,000,000 or $0.78 per share in fiscal year 2024 [10] Business Line Data and Key Metrics Changes - The expanding distributor network contributed $958,000 in sales, accounting for 86% of total revenues [4][8] - The company is focusing on increasing its market share in the companion animal market while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2,000,000,000 by 2026 [3] - The U.S. animal health market is projected to double to $11,300,000,000 by 2030, providing significant growth opportunities [19] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers [12] - Strategic partnerships and collaborations, such as with Digital Landia, are expected to enhance product visibility and market penetration [17][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to accelerate growth and expand into high-growth markets [19] - The company anticipates strong sales momentum and market penetration in fiscal year 2026, supported by recent advancements and partnerships [18] Other Important Information - The company has strengthened its leadership team and commercial operations, appointing experienced executives to key positions [21][22] - A successful offering of $5,000,000 in Series B convertible preferred stock was completed to support growth strategies [11] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - The conversion is on a one-to-one basis, with an additional 5,000,000 shares expected if fully converted [28][30] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge is around $800 per joint, varying between $500 to $1,200 depending on the complexity of the problem [33][35] Question: Can you talk a little bit about the human trials and their projected path? - The company is excited about the results from small and large animal studies, with potential applications in the human market for osteoarthritis, which is valued at approximately $11,200,000,000 in the U.S. [43][44]

Core Insights - PetVivo Holdings, Inc. reported a 17% increase in revenues to a record $1.1 million for the fiscal year ending March 31, 2025, driven by expansion into the companion animal market and strong sales of its lead product, Spryng with OsteoCushion Technology [5][7][31] - The company has made significant operational improvements, including a 24% reduction in operating loss to $8.1 million and a 27% decrease in net loss to $8 million [5][12] - PetVivo has entered strategic partnerships and expanded its product offerings, including a licensing agreement for PrecisePRP and a collaboration with Digital Landia for AI solutions in veterinary care [24][27][29] Fiscal 2025 Financial Highlights - Revenues increased by 17% to $1.1 million, with national distributor network sales rising 31% to $958,000, representing 85% of total revenues [5][12] - Gross profit rose 15% to $995,000, with a gross margin of 87.8% [5][12] - Net cash used in operating activities decreased by 40% to $2.9 million compared to fiscal 2024 [5] Fiscal 2025 Operational Highlights - Spryng has been administered by over 1,000 veterinary clinics across all 50 states since its introduction in 2021 [5][9] - The company signed an exclusive licensing agreement with VetStem, Inc. to commercialize PrecisePRP, receiving positive feedback from veterinarians [24][5] - A strategic alliance with Digital Landia focuses on AI technology for animal behavior analysis, currently in beta testing [27][29] Management Commentary - The CEO highlighted the strong performance and productivity of the fiscal year, emphasizing the expansion into the companion animal market and the introduction of innovative products [7][8] - The company anticipates continued growth driven by new partnerships and technologies that enhance its product platform [8][31] Fiscal 2026 Outlook - For the fiscal year ending March 31, 2026, the company expects record growth and improved bottom line as it continues to expand the use of Spryng and other new products [32][31] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [31]

Core Viewpoint - PetVivo Holdings, Inc. will hold a conference call on June 30, 2025, to discuss its financial results for the fiscal fourth quarter and year ended March 31, 2025 [1] Group 1: Conference Call Details - The conference call is scheduled for June 30, 2025, at 5:00 p.m. Eastern time [2] - A toll-free dial-in number and conference ID are provided for participants [2] - A replay of the webcast will be available after the conference call [3] Group 2: Company Overview - PetVivo Holdings, Inc. focuses on manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [4] - The company aims to leverage human therapies for companion animals in a capital and time-efficient manner [4] - PetVivo has a pipeline of products and holds a portfolio of twenty-one patents protecting its biomaterials and methods [5] Group 3: Key Products - The lead product, SPRYNG with OsteoCushion technology, is an intra-articular injection for managing lameness and joint-related afflictions in animals [5] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for veterinary use [5]

Company Highlights - PetVivo focuses on the estimated $11 billion companion animal veterinary care and product sales market[8, 103] - Spryng, with OsteoCushion Technology, is designed to restore joint mechanics for managing lameness and joint-related issues like osteoarthritis[8, 103] - The company has a strong IP portfolio with twelve U S and nine foreign issued patents[8, 22, 84, 103] Spryng Technology and Clinical Data - Spryng utilizes biocompatible materials similar to natural cartilage components to improve joint function[18] - Clinical studies show that 77.8% of dogs experienced a greater than 3-point reduction in total CBPI score after Spryng treatment for hip osteoarthritis[64] - Another canine stifle OA/CCL disease study showed that 55% of dogs had improved mGCPS at 28 days, and by 84 days, responders improved in VLS and LOAD scores by 50%[67] - Tolerance studies in both dogs and cats confirmed the excellent safety profile of Spryng, with no abnormalities observed in physical exams, CBC, or chemistry analysis after injections[58, 61] Market and Distribution - The U S pet spend increased from $123.6 billion in 2021 to $138 billion in 2022, with veterinary care and products being a leading growth driver at $11 billion in 2021[91] - PetVivo has distribution agreements with MWI and Covetrus, and engagements with wholesale partners like Clipper Distributing Company and Vedco, Inc[8, 49, 103]

Core Viewpoint - PetVivo Holdings, Inc. has successfully completed a $5 million equity financing, which will support the commercialization of its innovative veterinary medical products, including SPRYNG and PrecisePRP [1][4] Group 1: Financing Details - The company received $1 million from the full exercise of the remaining shares in a purchase option, completing the total offering of $5 million [1] - The purchase price for one share of Series B Convertible Preferred Stock was set at $1, with a conversion rate of one share for one common stock [1] - Prior to this exercise, the company had already received $4 million from the offering [1] Group 2: Product Information - SPRYNG is an intra-articular injectable device that utilizes OsteoCushion Technology, designed to manage joint pain and improve joint mechanics in animals [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product that provides a consistent dose of 4 billion platelets per vial, designed for easy use by veterinarians without the need for blood draws [3][7] Group 3: Company Overview - PetVivo Holdings focuses on the manufacturing and commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [6] - The company holds a portfolio of 21 patents protecting its biomaterials and products, indicating a strong intellectual property position [7]

Core Insights - PetVivo Holdings, Inc. has received $3 million from a partial exercise of a purchase option related to a $5 million equity financing offering, bringing the total received to $4 million to date [1][4] - The funds will be used to commercialize the company's key products, SPRYNG with OsteoCushion Technology and PrecisePRP, aimed at treating joint pain in companion animals [2][4] - SPRYNG is an injectable veterinary medical device that promotes joint health by integrating with animal tissue, while PrecisePRP is a convenient, off-the-shelf platelet-rich plasma product for intra-articular administration [3][8] Financial Overview - The offering consists of 5 million shares of Series B Convertible Preferred Stock priced at $1 per share, with a conversion rate of one preferred share to one common share [1] - An additional $1 million of the purchase option remains available for exercise by the investor [1] Product Details - SPRYNG utilizes sterilized extracellular matrix microparticles to restore joint mechanics and manage conditions like osteoarthritis [2] - PrecisePRP offers a consistent dose of 4 billion platelets per vial, designed for ease of use without the need for blood draws or centrifugation [3][8] Strategic Positioning - The investment strengthens the company's financial position and supports its growth strategy, including the expansion of its product portfolio [4] - PetVivo aims to leverage human medical therapies for companion animals, benefiting from a faster timeline to market compared to pharmaceuticals [6][7]

Core Viewpoint - PetVivo Holdings, Inc. has announced a strategic collaboration with Commonwealth to promote and clinically implement its innovative joint health products, SPRYNG and Precise PRP, in elite equine athletes [1][2][4]. Company Overview - PetVivo Holdings, Inc. is a biomedical device company focused on developing and commercializing medical devices and therapeutics for companion animals, holding twelve patents and six proprietary trade secrets [6]. - The company's lead product, SPRYNG, is designed for managing lameness and joint-related issues in animals, while Precise PRP is an off-the-shelf platelet-rich plasma product for veterinary use [6]. Collaboration Details - The partnership with Commonwealth aims to integrate SPRYNG and Precise PRP into care protocols for thoroughbred horses, focusing on joint health, performance longevity, and recovery [2][4]. - Both companies will also explore co-branded content and educational initiatives to raise awareness about joint wellness in the equine health community [3]. Leadership Statements - John Lai, CEO of PetVivo, emphasized the significance of the partnership with Commonwealth in showcasing the benefits of their technology for equine health [4]. - Chase Chamberlin, CEO of Commonwealth, highlighted the potential of SPRYNG and Precise PRP to enhance preventive and rehabilitative care for horses, aligning with new welfare protocols [4]. - Mike Eldred, Board Director at PetVivo, noted that the collaboration represents a significant step towards becoming a market leader in equine joint health and regenerative medicine [4].

Core Insights - Digital Landia, LLC has launched a minimum viable product (MVP) for its autonomous pet AI ecosystem, Agentic.Pet, in collaboration with PetVivo Holdings, Inc. [1] - The MVP is currently available for an invite-only beta testing phase, allowing pet industry professionals and enthusiasts to stress-test the platform [2][3] - The platform aims to enhance veterinary diagnostics, behavioral analysis, and nutritional advising through self-learning AI agents [2][4] Company Overview - Agentic.Pet is designed to autonomously create and evolve specialized AI agents that provide real-time insights for pet wellbeing, utilizing multi-modal data [5] - PetVivo Holdings, Inc. focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [7] - PetVivo has a portfolio of 21 patents and offers products like SPRYNG with OsteoCushion technology and PrecisePRP for veterinary use [8] Product Features - The MVP includes AI agents for blood tests, urine tests, and radiology, aimed at improving veterinary care [6] - Upcoming features include a pet identification add-on using facial recognition technology [3] - The platform is designed to support veterinarians and animal owners by streamlining clinical decision-making and administrative tasks [4]

Core Viewpoint - PetVivo Holdings, Inc. has entered into a Master Services Agreement with PiezoBioMembrane, Inc. to collaborate on the development of innovative functional biomaterials that can promote tissue and bone regeneration through piezoelectric stimulation [1][2]. Group 1: Partnership Structure and Strategic Benefits - The collaboration aims to combine PetVivo's extracellular matrix (ECM) biomaterial with PiezoBio's piezoelectric nanofibers to create a piezo-biomaterial that enhances healing and regeneration of damaged mammalian tissue and bone [2]. - PiezoBio's biodegradable piezoelectric nanomaterial acts as a battery-less electrical stimulator, providing a novel approach to tissue and bone regeneration [5]. Group 2: Product Development and Innovation - PetVivo has developed a biocompatible biomaterial that mimics mammalian tissue, which is crucial for minimizing adverse effects when implanted in animals or humans [3]. - The company's product SPRYNG® with OsteoCushion® Technology is an intra-articular injectable device that integrates with the animal's subsynovial tissue to restore joint mechanics and manage joint pain [4]. Group 3: Company Overview and Market Strategy - PetVivo focuses on manufacturing and commercializing innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [8]. - The company has a robust pipeline of products protected by twenty-one patents, including SPRYNG™ and PrecisePRP, which are currently available for commercial sale [9].

Core Insights - Digital Landia, in collaboration with PetVivo Holdings and its subsidiary, is set to launch AgenticPet.ai, the first autonomous pet care AI ecosystem, on May 23, 2025, aimed at transforming pet health and wellness through specialized AI agents [1][2] Group 1: Technology and Innovation - AgenticPet.ai utilizes multi-agent technology to create self-learning AI agents that provide insights into pet health, behavior, and nutrition [2][3] - The platform features specialized agents for veterinary diagnostics, behavioral analysis, nutritional advice, emotional wellness, and IoT data integration, enhancing comprehensive pet care [5][4] - The AI agents undergo rigorous digital certification exams to ensure expert-level mastery in various domains related to pet care [3] Group 2: Business Model and Market Strategy - AgenticPet.ai will adopt a tiered pricing structure, including a freemium tier, a premium subscription at $9.95/month, and an elite package at $24.95/month, making the technology accessible to a wide range of pet owners [4][5] - The platform is expected to onboard 100,000 freemium users within six months of launch, with a conservative estimate of a 10% conversion rate to paid subscriptions, potentially generating nearly $2 million in annual recurring revenue [7] Group 3: Strategic Positioning - PetVivo Holdings aims to align its clinically proven therapies with the innovative AI technology of AgenticPet.ai, enhancing its visibility and value in the veterinary care market [8] - The company focuses on leveraging human therapies for companion animals, which allows for a quicker market entry compared to more regulated pharmaceuticals [10]